Skip to main content

Ysios participates in the funding of 70 million dollars for BioVex

By 17 de November de 2009November 18th, 2020No Comments
< Back to news

Ysios participates in the funding of 70 million dollars for BioVex

, a venture capital firm specialised in biotechnology located at the barcelona Science Park, has participated alongside four international investors in the capital increase of BioVex, an American company specialised in the development of products for the prevention and treatment of cancer and infectious diseases.

The volume of this expansion, in which current specialised investors of the company – Forbion, Scottish Equity Partners and Credit Agricole Private Equity, amongst others- have also invested, reaches 70 million dollars, thereby making it one of the largest transactions in the scope of the biotechnological venture capital that has been performed this year at an international level.

Other first line investors such as Morningside Venture, MVM Life Sciences Partners, Ventech and Sectoral Asset Management have participated together with Ysios Capital Partners in this operation, which will enable BioVex to complete Phase III clinical studies of its drug OncoVEX.

This drug is an oncolytic drug developed for the treatment of recurrent melanoma that generates metastasis and has been proven successful in the trials conducted up until now –the results of which have been published in the Journal of Clinical Oncology-. Furthermore, BioVex will assign part of the funds obtained to financing the phase prior to the commercialisation of this product.

This is the third investment made by Ysios Capital Partners via the Ysios BioFund I, the largest venture capital of the Spanish market specialised in biotechnology, which was created in August 2008 with 69 million Euros.